PLRZ News

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement

Polyrizon Provides 2025 and Recent Highlights

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

LDB Capital Corp. Announces Definitive Agreement for Proposed Qualifying Transaction with Eventer Technologies Ltd. Ready to Announce with Confidence?